Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | PIP5K1C | O60331 | 1/20 | 0.33 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.33 |
| ▸ | PI4KA | P42356 | 1/20 | 0.33 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.33 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA4 | P22748 | 1/20 | 0.33 |
| ▸ | CA6 | P23280 | 1/20 | 0.33 |
| ▸ | CA5A | P35218 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
| ▸ | GLP1R | P43220 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3603956 | 0.74 | MEN1 (0.30) | — | |
| SCHEMBL3603960 | 0.73 | ENPP2 (0.38) | — | |
| SCHEMBL30252450 | 0.73 | GAA (0.38) | GLP1RKDM4E | |
| SCHEMBL16430495 | 0.73 | EDNRA (0.32) | — | |
| SCHEMBL3303195 | 0.73 | — | — | |
| SCHEMBL427846 | 0.73 | GAA (0.38) | GLP1RKDM4E | |
| Hydrochloric Acid SCHEMBL5203709 | 0.71 | GAA (0.44) | CA12CA1CA2CA9L3MBTL1 | |
| SCHEMBL31490392 | 0.71 | — | — | |
| SCHEMBL1255843 | 0.71 | — | — | |
| SCHEMBL12920693 | 0.70 | ALDH1A1 (0.36) | CA12CA1CA2CA6CA5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110183434-B | Oxadiazole compound and preparation method and application thereof | 南京林业大学 | 2022-07-12 | — | — | CN | disclosed |
| EP-3638669-A1 | SUBSTITUTED PYRROLOPYRIDINE-DERIVATIVES | Bayer Pharma Aktiengesellschaft (DE) | 2020-04-22 | — | — | EP | disclosed |
| WO-2018228920-A1 | SUBSTITUTED PYRROLOPYRIDINE-DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-12-20 | — | — | WO | disclosed |
| EP-1932835-B1 | METHOD FOR PRODUCING 2,3-DIHYDROPYRIDAZINE COMPOUND | SUMITOMO CHEMICAL CO (JP) | 2013-12-25 | — | — | EP | disclosed |
| US-8008485-B2 | Process for producing 2,3-dihydropyridazine compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-08-30 | — | — | US | disclosed |
| US-20090105475-A1 | PROCESS FOR PRODUCING 2,3-DIHYDROPYRIDAZINE COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-04-23 | — | — | US | disclosed |
| EP-1932835-A1 | METHOD FOR PRODUCING 2,3-DIHYDROPYRIDAZINE COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2008-06-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105475-A1 | PROCESS FOR PRODUCING 2,3-DIHYDROPYRIDAZINE COMPOUND | DDC, DHPS, QDPR | PIK3CD 3652/4885PIP5K1C 1143/4885PIK3CB 3210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.